Passage Bio, Inc. (PASG)

US — Healthcare Sector
Peers: QTTB  STOK  RVMD  BDTX  CABA 

Automate Your Wheel Strategy on PASG

With Tiblio's Option Bot, you can configure your own wheel strategy including PASG - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol PASG
  • Rev/Share 0.0
  • Book/Share 0.752
  • PB 8.5374
  • Debt/Equity 0.5377
  • CurrentRatio 3.7402
  • ROIC -0.958

 

  • MktCap 20032326.0
  • FreeCF/Share -0.6908
  • PFCF -0.4669
  • PE -6.2833
  • Debt/Assets 0.292
  • DivYield 0
  • ROE -0.9359

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 5
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation PASG Rodman & Renshaw -- Buy -- $7 Sept. 3, 2024

News

Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update
PASG
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral

PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural history Dose 2, 50% lower than Dose 1, substantially increased CSF PGRN levels at 30-days, reaching the upper limit of a healthy adult reference range Plan to amend upliFT-D protocol to include a prophylactic course of low dose anticoagulation and modify inclusion criteria to study patients earlier in disease progression Remain on track to seek regulatory feedback on FTD-GRN pivotal trial design in 1H 2026 PHILADELPHIA, June 23, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), …

Read More
image for news Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update
Passage Bio to Participate in Upcoming Investor Conferences
PASG
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral

PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in the following upcoming investor conferences:

Read More
image for news Passage Bio to Participate in Upcoming Investor Conferences

About Passage Bio, Inc. (PASG)

  • IPO Date 2020-02-28
  • Website https://www.passagebio.com
  • Industry Biotechnology
  • CEO William Chou
  • Employees 60
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.